PTH-glycine
PTH-glycine structure
|
Common Name | PTH-glycine | ||
|---|---|---|---|---|
| CAS Number | 2010-15-3 | Molecular Weight | 192.23800 | |
| Density | 1.39g/cm3 | Boiling Point | 292.1ºC at 760mmHg | |
| Molecular Formula | C9H8N2OS | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 130.5ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
J. Biol. Chem. 288(27) , 19359-69, (2013) Despite the fact that androgen deprivation therapy (ADT) can effectively reduce prostate cancer (PCa) size, its effect on PCa metastasis remains unclear. We examined the existing data on PCa patients treated with ADT plus anti-androgens to analyze ADT effects... |
|
|
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Cancer Res. 73(9) , 2926, (2013)
|
|
|
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
J. Steroid Biochem. Mol. Biol. 145 , 144-56, (2015) Recently two drugs, namely the antiandrogen MDV-3100 and the inhibitor of 17α-hydroxylase abiraterone have been accepted by the FDA for the treatment of castration-resistant prostate cancer (CRPC) with or without previous chemotherapy, with a prolongation of ... |
|
|
Enzalutamide in prostate cancer after chemotherapy.
N. Engl. J. Med. 367(25) , 2448; author reply 2448-9, (2012)
|
|
|
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
PLoS ONE 8(1) , e53701, (2013) Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation by the Androgen Receptor (AR), has the potential to provide insight int... |
|
|
Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
Prostate 74(9) , 959-69, (2014) Previously, we have shown that Y-box binding protein-1 (YB-1) regulates androgen receptor (AR) expression and contributes to castration resistance. However, the mechanism of YB-1 activation remains unknown. In this study, we aimed to elucidate the mechanism a... |
|
|
Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.
Int. J. Cancer 133(9) , 2225-33, (2013) The next-generation antiandrogen MDV3100 prolongs overall survival of patients with metastatic castration-resistant prostate cancer (CRPC). However, patient responses are variable, and survival benefit remains relatively small. Developing effective modality t... |
|
|
[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Prog. Urol. 23(1) , 1-7, (2013) Recently, new agents have been developed in the treatment of prostate cancer. Our aim was to review phase III studies that involved novel agents in the treatment of castration resistant prostate cancer.PubMed databases were searched for original articles publ... |
|
|
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.
Urology 81(2) , 381-3, (2013) To describe the case of a patient with castration-resistant, metastatic prostate cancer who achieved a complete and durable biochemical response after treatment with sipuleucel-T while continuing with enzalutamide and to explore the immunologic basis for such... |
|
|
Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.
Curr. Oncol. Rep. 15(2) , 69-75, (2013) Enzalutamide, formerly known as MDV3100, is an oral second generation androgen receptor (AR) inhibitor that was chosen from a screen of agents and shown in preclinical studies to have greater affinity for the AR than its predecessors without any agonistic eff... |